Healthcare Resource Use in Patients with Immune-Mediated Conditions Treated with Targeted Immunomodulators During COVID-19 Pandemic: A Retrospective Claims Analysis.
Healthcare Resource Use in Patients with Immune-Mediated Conditions Treated with Targeted Immunomodulators During COVID-19 Pandemic: A Retrospective Claims Analysis.
复制标题
在COVID-19大流行期间用靶向免疫调节剂治疗的免疫介导疾病患者的医疗保健资源使用：回顾性主张分析。
DOI：
10.1007/s12325-021-01906-4
复制
发表时间：
2021-10
影响因子：
3.8
通讯作者：
Naik HB
中科院分区：
文献类型：
--
作者：
Bergman M;Saffore CD;Kim KJ;Patel PA;Garg V;Xuan S;Naik HB
COVID-19大流行对常规医疗护理的影响可能导致免疫介导疾病患者的医疗资源使用发生变化。本研究的目的是确定治疗中断对在美国接受靶向免疫调节剂（TIM）治疗的COVID-19感染和未感染患者的影响。分析了2018年1月1日至2020年12月31日期间免疫介导疾病患者的IBM® MarketScan®研究数据库数据。在一个无COVID-19的患者队列中评估了医疗资源使用（HCRU），包括住院、急诊（艾德）访视、亲自门诊访视和呼吸结局，这些患者不间断与间断使用TIM。还在COVID-19患者队列中评估了治疗中断对HCRU和呼吸结局的影响。校正的logistic回归结果报告为校正的比值比（aOR）和95%置信区间。COVID-19（N = 787）和非COVID-19队列（N = 77，178）中约25%的患者经历了TIM治疗中断。在非COVID-19队列中，不间断使用TIM的患者住院的可能性比中断使用TIM的患者低20%（aOR = 0.80，95%CI 0.71-0.90）。与中断TIM使用的患者相比，中断TIM使用的患者发生艾德访视（aOR = 0.99，95% CI 0.91-1.08）和呼吸结局（aOR = 0.97，95% CI 0.71-1.31）的可能性相似。不间断使用TIM的患者进行门诊访视的可能性比中断使用TIM的患者高87%（aOR = 1.87，95% CI 1.81-1.94）。在COVID-19队列中也观察到了类似的发现。对真实世界索赔数据的分析表明，与免疫介导疾病患者中断TIM使用相比，不间断TIM使用与住院、艾德就诊或负面呼吸结局的可能性增加无关，无论COVID-19诊断如何。在线版本包含补充材料，可通过10.1007/s12325-021-01906-4获得。
The impact of the COVID-19 pandemic on routine medical care may result in altered healthcare resource use in patients with immune-mediated conditions. The aim of this study was to determine the impact of treatment interruptions in patients with and without COVID-19 infections who were treated with targeted immunomodulators (TIMs) in the USA. Data from the IBM® MarketScan® Research Databases were analyzed in patients with immune-mediated conditions from January 1, 2018, through December 31, 2020. Healthcare resource use (HCRU) including hospitalizations, emergency department (ED) visits, in-person outpatient visits, and respiratory outcomes was assessed in a cohort of patients without COVID-19 who had uninterrupted versus interrupted TIM use. The impact of treatment interruption on HCRU and respiratory outcomes was also evaluated in a cohort of patients with COVID-19. Results from adjusted logistic regression were reported as adjusted odds ratios (aORs) with 95% confidence intervals. Approximately 25% of patients in both the COVID-19 (N = 787) and non-COVID-19 cohorts (N = 77,178) experienced interruptions in TIM therapy. In the non-COVID-19 cohort, the likelihood of being hospitalized was 20% less in patients with uninterrupted versus interrupted TIM use (aOR = 0.80, 95% CI 0.71–0.90). Patients with uninterrupted TIM use had a similar likelihood of an ED visit (aOR = 0.99, 95% CI 0.91–1.08) and respiratory outcome (aOR = 0.97, 95% CI 0.71–1.31) versus patients with interrupted TIM use. The likelihood of having an in-person outpatient visit was 87% greater in patients with uninterrupted versus interrupted TIM use (aOR = 1.87, 95% CI 1.81–1.94). Similar findings were observed in the COVID-19 cohort. This analysis of real-world claims data showed that uninterrupted TIM use was not associated with an increased likelihood of hospitalizations, ED visits, or negative respiratory outcomes compared to interrupted TIM use among patients with immune-mediated conditions, regardless of COVID-19 diagnosis. The online version contains supplementary material available at 10.1007/s12325-021-01906-4.
登录
查看更多内容
影响因子：
13.8
作者：
Niaki, Omid Zahedi;Anadkat, Milan J.;Merola, Joseph F.
通讯作者：
Merola, Joseph F.
影响因子：
4.9
作者：
Favalli EG;Bugatti S;Klersy C;Biggioggero M;Rossi S;De Lucia O;Bobbio-Pallavicini F;Murgo A;Balduzzi S;Caporali R;Montecucco C
通讯作者：
Montecucco C
影响因子：
13.8
作者：
Gelfand, Joel M.;Armstrong, April W.;Ritchlin, Christopher T.
通讯作者：
Ritchlin, Christopher T.
DOI：
10.3899/jrheum.201017
发表时间：
2021-04
期刊：
The Journal of rheumatology
影响因子：
--
作者：
George MD;Venkatachalam S;Banerjee S;Baker JF;Merkel PA;Gavigan K;Curtis D;Danila MI;Curtis JR;Nowell WB
通讯作者：
Nowell WB
影响因子：
13.3
作者：
Mikuls, Ted R.;Johnson, Sindhu R.;Saag, Kenneth G.
通讯作者：
Saag, Kenneth G.